Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Core Insights - Bioventus Inc. reported strong financial results for Q4 and full-year 2024, highlighting a transformational year with significant revenue growth and improved profitability [2][3][6] Financial Performance - Q4 2024 worldwide revenue reached $153.6 million, marking a 13.5$573.3 million, an 11.9% increase compared to the previous year, with organic growth of 14.4% [6][12] - The net loss from continuing operations for Q4 2024 was $0.3 million, a significant improvement from a loss of$7.7 million in Q4 2023 [4][8] - Adjusted EBITDA for Q4 2024 was $28.3 million, up 28.3$22.0 million in the prior year [4][10] Revenue Breakdown - In Q4 2024, U.S. net sales for Pain Treatments were $62.8 million, an 18.7$46.4 million, up 16.8% [9] - International net sales for Q4 2024 totaled $18.4 million, reflecting a 10.9$24.7 million in proceeds, which is expected to enhance focus on core growth areas [14] - Bioventus aims to continue above-market revenue growth in 2025, projecting net sales between $560 million and$570 million, reflecting organic growth of approximately 6.1% to 8.0% [13][22] Operational Highlights - The company achieved five consecutive quarters of double-digit revenue growth in Pain Treatments and Surgical Solutions [14] - Cash from operations in Q4 2024 was $19.3 million, an increase of 86.3% compared to the previous year [10]